Common Contracts
2 similar Clinical Trial Agreement contracts
ContractClinical Trial Agreement • October 8th, 2021
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ This Clinical Trial Agreement (“Agreement”), effective as of the date of last signature and upon the publication in the Register of Contracts pursuant to Act nº 340/2015 Coll, (“Effective Date”) is entered into between Regeneron Pharmaceuticals, Inc., having an address at 777 Old Saw Mill River Road, Tarrytown, NY 10591 United States, Company ID No.: 1226128 represented by (“Sponsor”) and Všeobecná fakultní nemocnice v Praze, having an address at U Nemocnice 499/2, 128 08, Czech Republic, ID NO 00064165 represented by(“Institution”). Tato smlouva o klinickém hodnocení („smlouva“),nabývá účinnosti dnem posledního podpisu a po uveřejnění v Registru smluv, dle zákona č. 340/2015 Sb., se uzavírá mezi společností Regeneron Pharmaceuticals, Inc. se sídlem na adrese 777 Old Saw Mill River Road, Tarrytown, NY 10591, Spojené státy americké, IČO: 1226128 zastoupena („zadavatel“) a Všeobecnou fakultní nemocnicí v Praze, se sídlem na adrese U
ContractClinical Trial Agreement • March 9th, 2018
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ This Clinical Trial Agreement (“Agreement”), is entered into between Regeneron Pharmaceuticals, Inc., having an address at 777 Old Saw Mill River Road, Tarrytown, NY 10591 United States, Company ID No.: 1226128 represented by(“Sponsor”) and Všeobecná fakultní nemocnice v Praze, having an address at U Nemocnice 499/2, 128 08, Czech Republic, ID NO 00064165 represented by(“Institution”). Tato smlouva o klinickém hodnocení („smlouva“) se uzavírá mezi společností Regeneron Pharmaceuticals, Inc. se sídlem na adrese 777 Old Saw Mill River Road, Tarrytown, NY 10591, Spojené státy americké, IČO: 1226128 zastoupena(„zadavatel“) a Všeobecnou fakultní nemocnicí v Praze, se sídlem na adrese U Nemocnice 499/2, 128 08, Praha 2, Česká republika,IČ 00064165, zastoupena („zdravotnické zařízení“). WHEREAS, the Sponsor desires to conduct a clinical study (“Study”) of Praluent [Alirocumab] (SAR236553/REGN727) (“Investigational Drug”) as part of a
